SCHEMBL4014665

SCHEMBL4014665

COc1ccc(CC(=O)O)c([N+](=O)[O-])c1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.63
HSD17B10 Q99714 1/20 0.56
ALDH1A1 P00352 5/20 0.55
SMN1; SMN2 Q16637 4/20 0.54
NPC1 O15118 3/20 0.54
RAB9A P51151 3/20 0.54
MAPT P10636 3/20 0.51
MAPK1 P28482 3/20 0.51
KDM4E B2RXH2 2/20 0.51
AKR1C3 P42330 3/20 0.50
AKR1C2 P52895 3/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
MAOA P21397 1/20 0.49
MAOB P27338 1/20 0.49
LMNA P02545 1/20 0.49
PTGS1 P23219 1/20 0.49
POLB P06746 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2436193 1.00 CYP1A2 (0.63) CYP1A2HSD17B10ALDH1A1SMN1; SMN2NPC1
SCHEMBL4408882 0.89 CYP1A2 (0.57) CYP1A2HSD17B10ALDH1A1SMN1; SMN2NPC1
SCHEMBL14099278 0.88 ALDH1A1 (0.55) CYP1A2ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL3750320 0.88 HSD17B10 (0.60) CYP1A2HSD17B10ALDH1A1SMN1; SMN2NPC1
SCHEMBL10510363 0.87 ALDH1A1 (0.51) CYP1A2ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL10510370 0.87 ALDH1A1 (0.51) CYP1A2ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL7594064 0.87 ALDH1A1 (0.54) CYP1A2ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL2435599 0.87 PDGFRB (0.56) ALDH1A1SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL4405072 0.85 CYP1A2 (0.53) CYP1A2HSD17B10ALDH1A1SMN1; SMN2NPC1
SCHEMBL14334549 0.83 MAPT (0.57) ALDH1A1SMN1; SMN2NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528163-B2 N,N-Dibutyl-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]acetamide; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, intraoccular pressure in the eye MERCK & CO. INC. (US) 2009-05-05 US disclosed
EP-1581503-A4 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION MERCK & CO INC (US) 2007-07-25 EP disclosed
US-20060020000-A1 Ophthalmic compositions for treating ocular hypertension MERCK SHARP & DOHME CORP. 2006-01-26 US disclosed
EP-1581503-A2 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION Merck & Co., Inc. (US) 2005-10-05 EP disclosed
WO-2004043354-A2 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION MERCK & CO., INC. (US) 2004-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060020000-A1 Ophthalmic compositions for treating ocular hypertension KCNH2, KCNH3, KCNJ11 CYP1A2 2253/4885HSD17B10 1699/4885ALDH1A1 899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.